MiRNA-based anti-metastasis therapy: MiRNA-96 decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 28/April/2015, 15.15

Molecular therapy for CML: JUNB suppresses the expression of stem cell-enriched reprogramming protein Nanog via up regulation of its target gene, 28/April/2015, 15.04
April 28, 2015
Natural product-based Regenerative therapy for Diabetes mellitus: Vigna nakashimae extract increases human pancreatic beta cell replication via down regulation of its target gene DYRK1A, 28/April/2015, 22.33
April 28, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., MiRNA-based anti-metastasis therapy: MiRNA-96 decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 28/April/2015, 15.15, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: 

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year. 

The study presented here suggests that MiRNA-96, by decreasing the expression of its target gene, it may suppress the expression of PD-1.  Thereby, it may activate the immune system and inhibit metastatic progression. Thus, pharmacological formulations encompassing MiRNA-96 activators may be used to inhibit the progression of tumors.

Undisclosed information: How  MiRNA-96 suppresses the expression of PD-1

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.